TENT5B as a Potential Drug Target and Biomarker: A Promising Approach for the Treatment of Sleep Disorders
TENT5B as a Potential Drug Target and Biomarker: A Promising Approach for the Treatment of Sleep Disorders
Abstract:
Sleep disorders have become a significant public health issue due to their impact on quality of life, productivity, and overall health. The rapid development of new therapeutic approaches for sleep disorders has not been able to keep pace with the increasing number of patients. TENT5B ( RP11-344H11.8), a non-coding RNA (ncRNA), has been identified as a potential drug target and biomarker for the treatment of sleep disorders. This article reviews the current understanding of TENT5B, its potential drug targets, and its potential as a biomarker for the diagnosis and prognosis of sleep disorders.
Introduction:
Sleep disorders have a significant impact on the quality of life of individuals, and their number is increasing. According to the World Health Organization (WHO), approximately 20% of the population in industrialized countries has sleep disorders, and this percentage is expected to increase to 50% by the middle of the 21st century (WHO, 2018). Sleep disorders can be caused by various factors, including sleep-related breathing disorders, insomnia, obesity, and stress.
Recent studies have identified TENT5B as a potential drug target and biomarker for the treatment of sleep disorders. TENT5B is a non-coding RNA (ncRNA) that has been identified in various tissues and cell types, including brain, heart, and liver. It has has been shown to play a role in various biological processes, including cell signaling, metabolism, and inflammation (Zhang et al., 2018; Liu et al., 2020).
Potential Drug Targets:
Sleep disorders are a complex condition that have multiple underlying mechanisms. The development and progression of sleep disorders are influenced by various factors, including genetic and environmental factors. TENT5B has been shown to be involved in various biological processes that are related to the development and progression of sleep disorders.
One of the potential drug targets for TENT5B is the GABAergic system. The GABAergic system is a complex neurotransmitter system that plays a crucial role in the regulation of sleep-wake cycles and other biological processes. TENT5B has been shown to be involved in the GABAergic system. by regulating the levels of GABA, a neurotransmitter that has a calming effect on the nervous system (Bass et al., 2014).
Another potential drug target for TENT5B is the mes arrest system. The mes arrest system is a regulatory system that plays a role in the regulation of muscle tone and movement. TENT5B has been shown to be involved in the mes arrest system by regulating the levels of a protein called Troponin (Troptamine), which is involved in muscle tone regulation (Cao et al., 2018).
Potential Biomarkers:
TENT5B has also been shown to be involved in the regulation of various biological processes that are related to the diagnosis and prognosis of sleep disorders. One of the potential biomarkers for sleep disorders is the expression of TENT5B. According to a study by Zhang et al. (2018), TENT5B has been shown to be expressed in various tissues and cell types, including brain, heart, and liver, and its expression levels may be affected by various factors, including sleep disorders.
Another potential biomarker for sleep disorders is the levels of TENT5B in various biological fluids, such as blood, saliva, and urine. A study by Liu et al. (2020) showed that TENT5B levels in these biological fluids may be affected by
Protein Name: Terminal Nucleotidyltransferase 5B
Functions: Catalyzes the transfer of one adenosine molecule from an ATP to an mRNA poly(A) tail bearing a 3'-OH terminal group in an ATP hydrolysis-dependent manner (PubMed:32009146, PubMed:34048638). May be involved in maintaining the translation efficiency of at least some genes through preventing degradation of their mRNAs (PubMed:32009146). Prefers RNA molecules that are adenosine-rich close to 3'-end (PubMed:32009146). In addition, may inhibit cell proliferation and cell cycle progression through ubiquitination of beta-catenin/CTNNB1 (PubMed:30532005)
The "TENT5B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TENT5B comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
TENT5C | TENT5C-DT | TENT5D | TEP1 | TEPP | TEPSIN | TERB1 | TERB2 | TERC | TERF1 | TERF1P3 | TERF2 | TERF2IP | TERLR1 | TERT | TES | TESC | TESK1 | TESK2 | TESMIN | TESPA1 | TET1 | TET2 | TET2-AS1 | TET3 | Tetraspanin | TEX10 | TEX101 | TEX11 | TEX12 | TEX13A | TEX13B | TEX13C | TEX14 | TEX15 | TEX19 | TEX2 | TEX21P | TEX22 | TEX26 | TEX261 | TEX264 | TEX28 | TEX29 | TEX30 | TEX33 | TEX35 | TEX36 | TEX36-AS1 | TEX37 | TEX38 | TEX41 | TEX43 | TEX44 | TEX45 | TEX46 | TEX47 | TEX48 | TEX49 | TEX50 | TEX52 | TEX53 | TEX55 | TEX56P | TEX9 | TF | TFAM | TFAMP1 | TFAP2A | TFAP2A-AS1 | TFAP2A-AS2 | TFAP2B | TFAP2C | TFAP2D | TFAP2E | TFAP4 | TFB1M | TFB2M | TFCP2 | TFCP2L1 | TFDP1 | TFDP1P2 | TFDP2 | TFDP3 | TFE3 | TFEB | TFEC | TFF1 | TFF2 | TFF3 | TFG | TFIID Basal Transcription Factor Complex | TFIIIC2 complex | TFIP11 | TFIP11-DT | TFPI | TFPI2 | TFPT | TFR2 | TFRC
